Obermatt
See Similar Stocks →

Legend Biotech

NSQ:LEGN · US52490G1022
BiotechnologyMedium

360

30
EV / EBIT17
Price / Owner Earnings76
Cash yield1
Price/Sales91
EV / Gross Profit23
Price/Book31
Return on Capital66
Cash Return on Capital42
Return on Equity59
EBIT Margin39
Gross Profitability44
Accruals89
Owner Earnings Margin51
Sales growth77
Profit growth98
Reinvestment28
Price momentum14
Debt load21
Refinancing93
Debt Payback1
Liquidity73
Analyst ratings11
Opinion Changes20
Price Target Upside77
Market mood73
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Legend Biotech doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2015
Employees2,095
Websiteinvestors.legendbiotech.com
ISINUS52490G1022
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyStem Cell TherapyHematologyOncologyBiotechnologyHealth CareLife Science

Description

Legend Biotech Corporation is a global biopharmaceutical company. The company engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. The company operates through its ope…

Analysis

Middle-of-the-road

Legend Biotech Corporation sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
62
2026

All-time high

67

Mar 2026

All-time low

62

Jun 2026

Average rank

65

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
91
—
—
—
Price/Earnings
1
—
—
—
Price/Book
31
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
53
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Legend Biotech with its peers
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Cartesian Therapeutics
NMQ:RNAC
20
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Syndax Pharmaceuticals
NSQ:SNDX
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Monte Rosa Therapeutics
NSQ:GLUE
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Nkarta
NSQ:NKTX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →